{{short description|French healthcare company}}
{{Use mdy dates|date=September 2021}} {{Infobox company | name = BioSerenity | native_name_lang = fr | former_name = | type = Privately held company | industry = | founded = {{start date |2014|01|29}} | founder = Pierre-Yves Frouin | location_city = Paris | area_served = US, France, China | key_people = | products = Neuronaute, Cardionaute, Cardioskin<ref>{{cite journal|last1=Fouassier|first1=David|title=Assessment of signal quality measured with a smart 12-lead ECG acquisition T-shirt|journal=Annals of Noninvasive Electrocardiology|year=2020 |volume=25 |issue=1 |article-number=e12682 |publisher=Wiley|doi=10.1111/anec.12682 |pmid=31339208 |pmc=7050501 }}(citing {{PMID|31339208}})</ref> | services = Neurophy, Cardiophy, Somnophy<ref>{{cite journal|last1=Cairns|first1=Alyssa|title=Comparison of the macro and microstructure of sleep in a sample of sleep clinic hypersomnia cases.|date=February 2019|journal=Neurobiology of Sleep and Circadian Rhythms|volume=6|pages=62–69|publisher=Elsevier|doi=10.1016/j.nbscr.2019.02.001|pmid=31236521|pmc=6586604}}(citing {{PMID|31236521}})</ref> | num_employees = 400 | num_employees_year = 2019 | website = {{URL|https://www.bioserenity.com/}} | location_country = France }}
'''BioSerenity''' is a medtech company created in 2014 that develops ambulatory medical devices to help diagnose and monitor patients with chronic diseases<ref>{{cite web|title=La HealthTech, la mine d'or méconnue de la French Tech|url=https://www.latribune.fr/technos-medias/innovation-et-start-up/la-healthtech-la-mine-d-or-meconnue-de-la-french-tech-839460.html|website=latribune.fr|language=fr|date=February 12, 2020|access-date=September 10, 2021}}</ref> such as epilepsy.<ref>{{cite web|title=NHS could soon use smart outfit to diagnose epilepsy|url=https://www.newscientist.com/article/2091426-nhs-could-soon-use-smart-outfit-to-diagnose-epilepsy/|website=www.newscientist.com|language=English|date=June 1, 2016|access-date=September 10, 2021}}</ref> The medical devices are composed of medical sensors, smart clothing or consumables,<ref>{{cite news|title=Textiles connectés, où quand les vêtements scrutent les mouvements|url=https://www.letemps.ch/sciences/textiles-connectes-vetements-scrutent-mouvements|newspaper=Le Temps|language=fr|date=January 29, 2016|access-date=September 10, 2021}}</ref> a smartphone app for Patient Reported Outcome, and a web platform to perform data analysis through Medical Artificial Intelligence<ref>{{cite book|last1=Le Van Quyen|first1=Michel|title=2018 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP) |chapter=An Ensemble Learning Approach to Detect Epileptic Seizures from Long Intracranial EEG Recordings |date=2018|pages=856–860|publisher=IEEE|location=Calgary|doi=10.1109/ICASSP.2018.8461489|isbn=978-1-5386-4658-8|s2cid=52283583|url=https://hal.science/hal-03888415 |chapter-url=https://ieeexplore.ieee.org/document/8461489/authors#authors}}</ref><ref>{{cite news|title=Intelligence artificielle : la course aux bases de données|url=https://www.lemonde.fr/sciences/article/2017/05/08/intelligence-artificielle-la-course-aux-bases-de-donnees_5124406_1650684.html|newspaper=Le Monde.fr|date=May 8, 2017}}</ref> for detection of digital biomarkers.<ref>{{cite web|title=BioSerenity : l'intelligence artificielle et la data au service du patient|url=https://www.lesechos.fr/partenaires/bpifrance/bioserenity-lintelligence-artificielle-et-la-data-au-service-du-patient-1133273|website=Les Echos|language=fr|date=September 20, 2019|access-date=September 10, 2021}}</ref> The company initially focused on Neurology,<ref>{{cite news|title=Wearable technology: Clothing designed to save your life|work=BBC News|date=August 25, 2014|url=https://www.bbc.com/news/business-28844162|language=en}}</ref> a domain in which it reported contributing to the diagnosis of 30 000 patients per year.<ref>{{cite web|title=These Sensor-Studded Smart Clothes Just Might Save Your Life |url=https://www.wsj.com/articles/these-sensor-studded-smart-clothes-just-might-save-your-life-11631030505|website=www.wsj.com|language=English|date=September 7, 2021|access-date=September 10, 2021}}</ref> It now also operates in Sleep Disorders and Cardiology.<ref>{{cite web|title='Cardioskin' T-shirt tracks heart rhythm around the clock|url=https://www.cardiovascularbusiness.com/topics/electrophysiology-arrhythmia/cardioskin-t-shirt-tracks-heart-rhythm-24-hours|website=cardiovascularbusiness.com|date=September 13, 2018 |language=en}}</ref> BioSerenity reported it provides pharmaceutical companies with solutions for companion diagnostics.<ref>{{cite web|title=Dassault Systèmes Continues to Demonstrate Its Commitment to Life Sciences for Patient Experience by Investing in BioSerenity|url=https://markets.businessinsider.com/news/stocks/dassault-syst-mes-continues-to-demonstrate-its-commitment-to-life-sciences-for-patient-experience-by-investing-in-bioserenity-1028285932|website=businessinsider.com|language=en|date=June 19, 2019|access-date=September 10, 2021|archive-date=March 2, 2020|archive-url=https://web.archive.org/web/20200302145951/https://markets.businessinsider.com/news/stocks/dassault-syst-mes-continues-to-demonstrate-its-commitment-to-life-sciences-for-patient-experience-by-investing-in-bioserenity-1028285932|url-status=dead}}</ref>
== Company history == BioSerenity was founded in 2014, by Pierre-Yves Frouin. The company was initially hosted at the ICM Institute (Institute du Cerveau et de la Moëlle épinière),<ref>{{cite web|title=BioSerenity|url=https://ipeps.icm-institute.org/startups/bioserenity.html|website=www.icm-institute.org/}}</ref><ref>{{cite news|title=Un tee-shirt qui diagnostique l'épilepsie|url=https://www.lemonde.fr/sciences/article/2014/09/30/un-tee-shirt-qui-diagnostique-l-epilepsie_4497111_1650684.html|newspaper=Le Monde.fr|date=September 30, 2014}}</ref> in Paris, France.
'''Fund Raising'''
* June 8, 2015 : The company raised a $4 million seed round with Kurma Partners and IdInvest Partners<ref>{{cite web|title=KURMA ANNOUNCES THE FIRST INVESTMENT OF THEIR NEWLY LAUNCHED DIAGNOSTICS FUNDS IN THE START UP COMPANY BIOSERENITY|url=http://kurma-partners-website-backend.cdn.prismic.io/kurma-partners-website-backend%2F283e2b75-0733-4ea1-8fd2-5a7bc264a21c_pr_kdx_bioserenity_8__june_2015.pdf|website=www.kurmapartners.com/|date=June 8, 2015|access-date=September 10, 2021}}</ref> * September 20, 2017 : The company raised a $17 million series A round with LBO France, IdInvest Partners and BPI France<ref>{{cite web|title=BioSerenity, champion français de la e-santé, lève 15 millions d'Euros|language=fr|trans-title=|url=https://lyonbiopole.com/wp/wp-content/uploads/2017/10/FR_CP_BioSerenity_leve_15MEUR-20092017.pdf|website=lyonbiopole.com/|date=September 20, 2017|access-date=September 10, 2021|archive-date=June 16, 2021|archive-url=https://web.archive.org/web/20210616205810/https://lyonbiopole.com/wp/wp-content/uploads/2017/10/FR_CP_BioSerenity_leve_15MEUR-20092017.pdf|url-status=dead}}</ref> * June 18, 2019 : The company raised a $70 million series B round with Dassault Systèmes, IdInvest Partners, LBO France and BPI France<ref>{{cite web|title=BioSerenity, champion MedTech spécialisé dans les solutions de diagnostic et de télé-expertise, lève 65 millions d'euros pour étendre son activité aux Etats-Unis et approfondir ses solutions IoT et d'Intelligence Artificielle|language=fr|trans-title=|url=https://www.lbofrance.com/var/fichiers/cp-serie-b-18062019-frana-ais.pdf|website=www.lbofrance.com|date=June 18, 2019|access-date=September 10, 2021|archive-date=November 4, 2019|archive-url=https://web.archive.org/web/20191104182657/https://www.lbofrance.com/var/fichiers/cp-serie-b-18062019-frana-ais.pdf|url-status=dead}}</ref>
'''Receivership and court-ordered sale'''
On 21 July 2023, BioSerenity SAS entered cessation of payments. The Paris Commercial Court (''Tribunal de commerce de Paris'') opened receivership proceedings (''redressement judiciaire'') on 3 August 2023.<ref name="societe-com">{{cite web |url=https://www.societe.com/societe/bioserenity-799995782.html |title=BIOSERENITY (799995782) - Tribunal de commerce de Paris, jugement P202302177 |publisher=societe.com |access-date=2026-05-07}}</ref> On 10 November 2023, the court approved a sale plan (''plan de cession'') of the company's assets to Jolt Capital for €24 million and ordered the judicial liquidation of the original BioSerenity SAS entity.<ref name="usine-digitale">{{cite news |url=https://www.usine-digitale.fr/article/la-medtech-francaise-bioserenity-sauvee-de-la-liquidation-par-jolt-capital-pour-24-millions-d-euros.N2195178 |title=La medtech française BioSerenity sauvée de la liquidation par Jolt Capital pour 24 millions d'euros |work=L'Usine Digitale |date=2023-11-14 |language=fr}}</ref><ref name="societe-com" /> Operations continued under the new ownership.
'''Acquisitions'''
In 2019, BioSerenity announced the acquisition of the American Company SleepMed<ref>{{cite web|title=BioSerenity rachète l'américain SleepMed|url=https://business.lesechos.fr/entrepreneurs/financer-sa-creation/0601908938738-bioserenity-rachete-l-americain-sleepmed-331844.php#Xtor=AD-6000|last=Loye|first=Deborah|website=Les Echos Executives|language=fr|date=September 23, 2019|access-date=September 10, 2021}}</ref> and Novasom<ref>{{Cite web |last=Christie |first=Jim |date=September 24, 2019 |title=IN BRIEF: BioSerenity to buy NovaSom out of bankruptcy |work=Reuters |url=https://www.reuters.com/article/legal/in-brief-bioserenity-to-buy-novasom-out-of-bankruptcy-idUSL2N26E1UQ/ |access-date=January 22, 2026}}</ref>
'''Development'''
In 2019, was working with over 200 Hospitals.
In 2020, BioSerenity was one of the five French manufacturers (Savoy, BB Distrib, Celluloses de Brocéliande, Chargeurs) working on the production of sanitary equipment including FFP2 masks at request of the French government.<ref>{{Cite web |date=2020-07-28 |title=Les usines de l'Hexagone en ordre de bataille pour les protections sanitaires |url=https://www.lefigaro.fr/societes/les-usines-de-l-hexagone-en-ordre-de-bataille-pour-les-protections-sanitaires-20200728 |access-date=2022-06-30 |website=LEFIGARO |language=fr}}</ref>
In 2021, the Neuronaute was used by approximately 30,000 patients per year.<ref>{{Cite journal |last=Ledoux |first=Aurélie |date=2009 |title=Vidéos en ligne : la preuve par l'image ? |url=http://dx.doi.org/10.3917/espri.0903.0095 |journal=Esprit |volume=Mars/avril |issue=3 |pages=95–106 |doi=10.3917/espri.0903.0095 |issn=0014-0759|url-access=subscription }}</ref>
In 2023, the company launched the Icecap, a single use EEG solution<ref>{{Cite web |title=About us |url=https://group.bioserenity.com/en/nous-connaitre |access-date=2026-01-22 |website=groupe bioserenity |language=en}}</ref><ref>{{Cite web |title=ICECap |url=https://bioserenity.com/icecap/ |access-date=2026-01-22 |website=BioSerenity |language=en-US}}</ref> and its A.I. model for Sleep Disorders with teams from Stanford University.<ref>{{Cite web |title=Research |url=https://bioserenity.com/research/ |access-date=2026-01-22 |website=BioSerenity |language=en-US}}</ref><ref>{{Cite journal |last1=Rahmouni |first1=Mohamed |last2=Bussalb |first2=Aurore |last3=Elbaz |first3=Maxime |last4=Jubien |first4=Guillaume |last5=Gimenez |first5=Ulysse |date=2024-03-01 |title=Algorithmes de détection de micro-éveils de haute performance avec un modèle de deep learning |url=https://www.sciencedirect.com/science/article/pii/S1769449323003631 |journal=Médecine du Sommeil |series=Le congrès du sommeil |volume=21 |issue=1 |pages=8 |doi=10.1016/j.msom.2023.12.014 |issn=1769-4493|url-access=subscription }}</ref><ref>{{Cite book |last1=Hanif |first1=Umaer |last2=Gimenez |first2=Ulysse |last3=Cairns |first3=Alyssa |last4=Lewin |first4=Daniel |last5=Ashraf |first5=Nisar |last6=Mignot |first6=Emmanuel |chapter=Automatic Detection of Chronic Insomnia from Polysomnographic and Clinical Variables Using Machine Learning |date=July 2023 |title=2023 45th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC) |chapter-url=https://pubmed.ncbi.nlm.nih.gov/38083711 |volume=2023 |pages=1–5 |doi=10.1109/EMBC40787.2023.10340587 |issn=2694-0604 |pmid=38083711 |isbn=979-8-3503-2447-1 }}</ref>
In 2025, the company was performing more than 45,000 EEGs (electroencephalograms), 8,000 PSGs (polysomnographies), and 5,000 ECGs (electrocardiograms) each year.<ref>{{Cite web |title=Emmanuel Mougeotte is BIOSerenity's new CEO |url=https://www.jolt-capital.com/news/emmanuel-mougeotte-is-bioserenitys-new-ceo |access-date=2026-01-22 |website=Jolt Capital |language=en-GB}}</ref> The company launched a new EEG A.I. model<ref>{{Citation |last1=Bettinardi |first1=Ruggero G. |title=BioSerenity-E1: a self-supervised EEG model for medical applications |date=2025-03-13 |url=http://arxiv.org/abs/2503.10362 |access-date=2026-01-22 |arxiv=2503.10362 |last2=Rahmouni |first2=Mohamed |last3=Gimenez |first3=Ulysse}}</ref> and signed an agreement to distribute its solutions in the USA through Stratus.<ref>{{Cite web |title=Stratus Partners with BioSerenity to Become U.S. Distributor of IceCap® Product Line |url=https://stratusneuro.com/resources/stratus-to-become-us-distributor-of-icecap |access-date=2026-01-22 |website=stratusneuro.com |language=en}}</ref>
In November 2025, Emmanuel Mougeotte, former CEO of CompuGroup Medical France, became CEO of the company <ref>{{Cite web |title=Emmanuel Mougeotte is BIOSerenity's new CEO |url=https://www.jolt-capital.com/news/emmanuel-mougeotte-is-bioserenitys-new-ceo |access-date=2026-01-22 |website=Jolt Capital |language=en-GB}}</ref> and in January 2026, Pierre-Yves Frouin, founder of BioSerenity concluded his tenure and exited the company.<ref>{{Cite web |title=Former CEO concludes his tenure after 11 years |url=https://www.jolt-capital.com/news/former-ceo-concludes-his-tenure-after-11-years |access-date=2026-01-22 |website=Jolt Capital |language=en-GB}}</ref>
In March 2026, the company opened an affiliate in Germany.<ref>{{Cite web |title=Unternehmensregister - Die zentrale Plattform zu Unternehmensdaten |url=https://www.unternehmensregister.de/en/search?areas=all&companySearchTerm=bioserenity&companyName=bioserenity&searchToken=TbcLivN_9nBG9zayneCSonuhQZdYKfYhFI6VmDe4GSA_w555RnEnurctdhX8n3pbEVzlJHBeNRYIOdUS6JpjL5Uz7mNiYXcXT7IVZJc264UPwGshN3ZqjyaW9CUwWhtguMdYDIdLt41r5dW60TKFV7iPYc8N_KkW2gcNXHAvR-Y3icGgxFyOzBESVdok5aFkKarSCUk7 |access-date=2026-04-24 |website=www.unternehmensregister.de}}</ref>
== Awards == * BioSerenity is one of the Disrupt 100<ref>{{cite web|title=BioSerenity|url=http://2016.disrupt100.com/company/bioserenity/|website=disrupt100.com|language=en|access-date=September 10, 2021|archive-date=February 27, 2020|archive-url=https://web.archive.org/web/20200227021515/http://2016.disrupt100.com/company/bioserenity/|url-status=dead}}</ref> * BioSerenity joined the Next40<ref>{{cite web|title=BioSerenity|url=https://next40.org/bioserenity/|website=Next40.org|date=November 25, 2014 |language=fr-FR|access-date=September 10, 2021}}</ref> * BioSerenity was selected by Microsoft and AstraZeneca in their initiative AI Factory for Health<ref>{{cite web|title=These 6 startups were selected to join Microsoft and AstraZeneca's AI Factory for Health|url=https://www.bioportfolio.com/news/article/4233478/These-6-startups-were-selected-to-join-Microsoft-and-AstraZenecas-AI-Factory.html|website=www.bioportfolio.com|date=March 12, 2020 |language=en}}</ref> * BioSerenity accelerated at Stanford's University StartX program<ref>{{cite web|title=Companies|url=https://startx.com/companies|website=www.startx.com|language=en}}</ref>
== References == <references />
== External links == * {{official website|https://www.bioserenity.com/}} * [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K170138 FDA Clearance Neuronaute] * [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K173248 FDA Clearance Cardioskin] * [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K110486 FDA Clearance Accusom]
{{authority control}}
Category:Health care companies of France Category:Machine learning Category:Health care companies established in 2014 Category:French companies established in 2014